Livzon Pharmaceutical Group Inc. (LIVZON PHARMA) has obtained a Notice of Drug Clinical Trial Approval (2026LP01115) from China’s National Medical Products Administration, authorising clinical evaluation of JP-1366 Tablet in combination with antibiotics for the eradication of Helicobacter pylori.

JP-1366 is an innovative potassium-competitive acid blocker (P-CAB). Within the planned quadruple regimen—JP-1366 Tablet, amoxicillin, clarithromycin and bismuth potassium citrate—the acid suppressant directly targets proton pumps without gastric-acid activation, providing rapid, potent and sustained acid suppression. All three core agents (acid suppressant, antibiotic and bismuth agent) are independently developed by LIVZON PHARMA, underscoring pipeline depth and potential product synergies.

The company’s broader JP-1366 franchise continues to advance: a marketing authorisation application for JP-1366 Tablet in reflux esophagitis was accepted in August 2025, and an injectable formulation entered Phase II trials for peptic-ulcer bleeding in October 2025.

Cumulative direct R&D investment in JP-1366 Tablet has reached RMB 227.81 million.

Management highlights that commercialisation remains contingent on successful clinical outcomes and subsequent NMPA approvals, with timing and results subject to typical drug-development uncertainties.